Aurora Cannabis Inc. has announced it will host an investor conference call on November 12, 2026, to discuss its financial results for the second quarter of 2027. This call is significant as it reflects the company's ongoing commitment to transparency and engagement with its investors.

Scheduled for 8:00 a.m. Eastern Time, the call will feature Miguel Martin, Executive Chairman and Chief Executive Officer, along with Simona King, Chief Financial Officer. They will discuss the financial results and take questions from investors.

Background

Aurora Cannabis Inc. is a leading global medical cannabis company, incorporated in Canada. It operates under the Standard Industrial Classification (SIC) code 2833, which pertains to medicinal chemicals and botanical products. The company trades on the Nasdaq and TSX under the ticker symbol ACB.

The most recent SEC filing was made on October 29, 2026, as a Form 6-K, which is a report of a foreign private issuer. Aurora has been active in filing various forms, including multiple SC14D9F/A submissions, indicating ongoing corporate activities and potential shareholder communications.

What the Filing Says

The filing details that Aurora Cannabis will report its financial results prior to the market opening on the same day as the call. The company has emphasized its commitment to keeping shareholders informed and engaged.

Impact

This announcement may impact various stakeholders, including investors, analysts, and competitors in the medicinal chemicals and botanical products industry. Investors will be keen to assess the company's performance and strategic direction, especially in light of recent market trends and competitive pressures.

What's Next

The upcoming investor conference call is set for November 12, 2026. It will provide an opportunity for stakeholders to gain insights into Aurora's financial health and future prospects. The filing does not specify any additional actions or developments beyond this call.